GlaxoSmithKline Issued European Marketing Authorization for Addison Whitney Creation
CHARLOTTE, NORTH CAROLINA, June 26, 2008 – GlaxoSmithKline recently received marketing authorization from the European Commission for Volibris® (ambrisentan), a compound indicated to improve exercise capacity in Pulmonary Arterial Hypertension (PAH) patients. Ambrisentan is the first European approved medicine for the treatment of PAH in WHO Functional Class II patients.Myogen, later acquired by Gilead®, engaged Addison Whitney to develop and test proprietary name candidates for ambrisentan. Gilead now owns the US marketing rights for ambristentan, as well as the trademarks Volibris and Letairis (the US brand name). Myogen previously awarded EU marketing rights to GlaxoSmithKline.
Addison Whitney developed and validated the name Volibris for ambristentan. The name suggests freedom and liberation from the symptoms of PAH, specifically the reduced energy levels limiting the patient’s physical activity. The US and European brand names for ambrisentan, both created by Addison Whitney, are connected by the shared suffix.
For more information, please call Lizzy Guterma at 704-697-4055 or lizzy.guterma@addisonwhitney.com or visit www.addisonwhitney.com.
About Addison Whitney
Addison Whitney is a global full-service brand consulting firm. Founded in 1991, the firm has extended its services to offer branding expertise in the areas of verbal branding, visual branding, brand strategy, and research and analysis. Clients come to Addison Whitney from industries including: consumer, technology, business to business and other market segments. Addison Whitney health, a specialized healthcare division of Addison Whitney, serves the branding needs of pharmaceutical, biotechnology, life science, and medical specialties. For more information, visit www.addisonwhitney.com.
« BACK TO PRESS RELEASES
